Aurobindo Pharma gets USFDA nod for Sumatriptan
Aurobindo Pharma has received tentative approval from the US Food and Drug Administration to manufacture and market Sumatriptan Succinate tablets 25mg, 50mg and 100mg.
By INDIATIMES NEWS NETWORK |
MUMBAI: Aurobindo Pharma has received tentative approval from the US Food and Drug Administration to manufacture and market Sumatriptan Succinate tablets 25mg, 50mg and 100mg.
Sumatriptan Succinate tablets are the generic equivalent of GlaxoSmithKline's Imitrex Tablets, which are indicated for the treatment of acute migraine headaches.
At 10:23 am, Aurobindo Pharma shares were up 2.06 per cent at Rs 300.45 on BSE.
Sumatriptan Succinate tablets are the generic equivalent of GlaxoSmithKline's Imitrex Tablets, which are indicated for the treatment of acute migraine headaches.
At 10:23 am, Aurobindo Pharma shares were up 2.06 per cent at Rs 300.45 on BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
